Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 27NIH 12INDUSTRY 10NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 23Breast Neoplasms 23Carcinoma, Non-Small-Cell Lung 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Multiple Myeloma 14Colorectal Neoplasms 12Lymphoma 10Neoplasms 9Lung Neoplasms 9Melanoma 8Leukemia, Myeloid, Acute 8Pancreatic Neoplasms 7Lymphoma, Non-Hodgkin 7Leukemia, Biphenotypic, Acute 6Burkitt Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Ependymoma 5Endometrial Neoplasms 5Colonic Neoplasms 5Wilms Tumor 4Rectal Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Osteosarcoma 4Neoplasm Metastasis 4Medulloblastoma 4Malignant Solid Neoplasm 4Lymphoma, Mantle-Cell 4

Interventions

X-Rays 1Specimen Handling 1Phantoms, Imaging 1Bone Density 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Sarcoma, Ewing × 90 days × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡